Artificial Intelligence and Polyclonal Antibody Sequencing Redefining Antibody Discovery

1. Latest Advances in Antibody Discovery Technologies

1. Single B-cell Isolation and Sequencing:

Isolating and sequencing single B cells can help us gain a deeper understanding of B cell diversity and specificity. This method allows us to clarify the relationship between sequences and cells, thereby uncovering antibodies with unique properties. These antibodies may have high affinity for targets, effectively combat pathogens, or participate in the body's autoimmune responses.

2. Display Library Design:

The design of phage display libraries and other display technologies is another approach to antibody discovery, significantly increasing the diversity of antibody structures and sequences. This provides strong support for developing antibodies against hard-to-target antigens. Compared to original libraries, libraries derived from immune donors can produce antibodies with higher expression levels, affinity, and specificity for target antigens, injecting new vitality into antibody drug development. Additionally, the generation of synthetic libraries allows complete control over antibody sequences through de novo design, which not only helps eliminate unfavorable sequences but also significantly shortens the downstream engineering and optimization processes, enhancing research and development efficiency. Recent advances in library design focus mainly on sequence optimization, precisely regulating antibody structures and characteristics, such as stability and solubility, thus improving antibody developability.

3. Computer Simulation:

In recent years, computer simulation technology has become increasingly prevalent in antibody research, often used for screening, selecting, and optimizing potential antibody sequences after discovery activities. This method can help us design antibody characteristics (such as binding sites, binding kinetics, etc.) more precisely, enhancing antibody efficacy. Additionally, it can predict interactions of antibodies with biological environments, aggregation, and stability. Thus, using computer simulations is expected to reduce reliance on expensive and time-consuming trial-and-error experiments, promoting efficient antibody research and development.

2. Major Challenges in Antibody Discovery

1. Difficult-to-Target Antigens and New Drug Targets

Difficult-to-target antigens and new drug targets are major challenges in antibody discovery and antibody drug design. Transmembrane protein receptors, which account for 20-30% of the human proteome and 60% of current drug targets, are particularly challenging. Due to the structural complexity, significant conformational variability, low immunogenicity, and lack of soluble forms of these receptors, developing functional antibodies against them is difficult.

2. Applicability of Animal Models

In antibody discovery, the use of in vivo models is often limited by the applicability of animal models, which can pose challenges for early development and subsequent testing. Especially when host tissues express the target antigen, immune tolerance may hinder the induction of an effective immune response, increasing research difficulty. Additionally, cross-reactivity issues need special attention in preclinical studies and safety testing. Due to similarities in protein structure, sequence homology, or expression patterns between different species, antibodies developed in animal models may unexpectedly cross-react with similar antigens.

3. Immunogenicity

Immunogenicity is also a critical concern in antibody development, especially when using animal models to produce antibodies for humans. Differences in post-translational modifications, antibody structures, and amino acid sequences may trigger immune responses against the therapeutic drug itself, leading to the production of anti-drug antibodies and potentially causing adverse reactions.

4. Accessing a Diverse Antibody Library

Accessing a diverse and functionally relevant antibody library is a major technical challenge in antibody discovery. Taking B-cell sequencing as an example, although 2-3% of B cells in peripheral blood are derived from bone marrow and spleen, this portion comprises only a tiny fraction of the entire B-cell population. Among these circulating B cells, the proportion that can differentiate into antibody-secreting plasma cells is even smaller. Therefore, relying solely on B-cell sequencing to explore the antibody library significantly limits our ability to comprehensively access the entire antibody repertoire.

5. Discovering Antibodies with Specific Functions

In antibody discovery, our ideal goal is to obtain diverse antibodies targeting multiple epitopes with various functions. Although the discovery process may yield binders to the target antigen, finding antibodies with specific functions (such as agonists or receptor blockers) is indeed a highly challenging task.

From antibody discovery to final application, identifying antibodies is just a small part of the entire process. Despite some antibodies exhibiting superior functionality, specificity, and affinity, they may not always be ideal candidates during actual development. Antibody stability issues, such as degradation, aggregation during solution or administration, and formulation complexity, are challenges that need to be overcome for successful development of antibody drug candidates. Additionally, many antibody drug designs face challenges in economically efficient characterization, developability assessment, and efficacy and safety prediction during the early stages.

3. How to Mitigate Risks in Antibody Discovery

1. Target Validation

Strict target validation is crucial as it helps us accurately identify the most therapeutically promising directions and allocate resources for research. We should prioritize targets with thorough validation and strong biological rationale, which not only increases the likelihood of success but also effectively reduces the risk of investing in targets with limited therapeutic potential.

2. Combining Multiple Strategies and Modalities

There is no 'one-size-fits-all' method for antibody discovery. Strategies that have proven effective in other studies may not replicate the same success. Employing multiple strategies, such as using various immunization methods across different species, can increase the chances of success. Additionally, combining multiple discovery modalities, such as polyclonal antibody sequencing, B-cell sequencing, and computer modeling, can enhance the likelihood of success. This approach not only integrates the advantages of various methods but also accelerates the early discovery phase of therapeutic development. In scenarios where computational modeling and AI-driven antibody discovery run parallel to in vivo approaches, we can anticipate and prioritize potential antibody candidates. This method reduces the need for extensive experimental testing and streamlines the discovery process.

3. Polyclonal Technology

Utilizing REpAb technology for polyclonal antibody sequencing provides a new avenue for antibody discovery, accelerating the discovery process. Once immunization is complete, we can quickly initiate the discovery process by collecting highly enriched and functionally significant antibodies from serum. Subsequently, using proteomics-based methods, these antibodies are sequenced and further characterized and analyzed through recombinant expression. This method eliminates the need for cell sorting, immortalization, and purification steps before characterization.

4. Conducting Antibody Characterization

Regular antibody characterization throughout the antibody discovery and development process has proven to be an extremely effective strategy. In the early discovery phase, using advanced technologies to assess the biophysical and functional properties of antibodies, as well as cross-reactivity and performance, ensures that candidate drugs do not incur costs upon failure during cell line development and formulation processes.

4. High-Throughput Screening

High-throughput antibody screening assays are valuable for rapidly evaluating a large number of potential antibodies, allowing the selection of candidate antibodies with the desired properties. High-throughput methods using surface plasmon resonance (SPR) for kinetic analysis can quickly analyze the kinetics and affinity properties of a series of antibodies, selecting antibodies with different affinities, binding rates, and dissociation rates, enriching the diversity of antibody candidates. Similarly, conducting epitope grouping and localization experiments using hydrogen-deuterium exchange mass spectrometry (HDX-MS) provides information on different binding epitopes, offering strong support for downstream selection. Early cell line development work is often seen as 'finding a needle in a haystack.' To improve success rates, we need to use rapid analytical techniques to enhance sequence generation and PTM (e.g., glycosylation characteristics) analysis. In this process, mass spectrometry-based real-time peptide mapping and glycosylation analysis are undoubtedly ideal tools.

By combining these strategies, researchers can streamline and enhance the efficiency of antibody discovery efforts, maximizing the chances of successfully identifying therapeutic candidate antibodies and laying a solid foundation for the smooth initiation of early production.

4. Impact of Artificial Intelligence (AI) and Machine Learning (ML) on Antibody Discovery

AI and ML have played a crucial role in enhancing various aspects of antibody discovery. In target identification, AI-driven algorithms can analyze large volumes of biological data, such as proteomics, genomics, and disease pathways, to identify potential therapeutic targets. The rise of generative AI offers unprecedented opportunities for novel antibody design, entirely based on algorithmic generation without relying on experimental data or biological knowledge. However, due to limitations in training data, the complexity of antibody structures and functions, and the biological diversity and variability of the immune system, the effectiveness of this approach has yet to be fully validated.

5. Impact of Polyclonal Antibody Sequencing on Antibody Discovery

Proteomics and mass spectrometry-based antibody discovery effectively address several challenges faced by other discovery technologies.

REpAb polyclonal antibody sequencing is a significant method for antibody discovery utilizing proteomics and mass spectrometry technology. One of its main advantages is its ability to leverage the natural immune system to expand the search range for antibodies. Biologically, peripheral blood samples serve as a critical bridge connecting germinal centers and bone marrow. Using proteomics-based methods to analyze serum immunoglobulins allows direct analysis of antibodies secreted from the bone marrow. These antibodies are often challenging to capture through traditional methods like B-cell sequencing because the differentiation properties of B cells make it exceedingly difficult to obtain samples representing the overall immune diversity.

Furthermore, polyclonal sequencing is not limited by the acquired B cells or phage library, allowing analysis of the entire antibody library at any given time. This method can analyze different antibody libraries and identify candidate antibodies with the desired functionality and specificity that might be missed using other methods.

The REpAb polyclonal antibody sequencing technology can also identify antibody candidates of biological significance. The immunoglobulins present in the serum have undergone extensive affinity maturation and somatic hypermutation screening by the host immune system, producing functional antibodies. Since these immunoglobulins are abundantly produced by the natural host, concerns about production yield, post-translational modifications, stability, immunogenicity, and aggregation tendencies are generally minimized. However, comprehensive biophysical and performance characterization of antibodies remains essential to ensure their practical application.

The REpAb polyclonal antibody sequencing technology employs a de novo sequencing strategy, allowing the direct resolution of amino acid sequences from MS/MS spectra without relying on any known protein or DNA sequence information. This method breaks species limitations, showcasing its unique advantages, especially when preparing antibodies against conserved proteins using different hosts. During the in vivo affinity maturation process, antibodies undergo extensive somatic hypermutation, resulting in high sequence diversity. In the absence of reference sequences, de novo sequencing becomes the most effective method for antibodies. Additionally, when other methods (such as hybridoma technology) are not feasible for certain species, the REpAb polyclonal antibody sequencing technology provides a new perspective.

Baitai Pack Biotechnology - A quality service provider for biopharmaceutical characterization and multi-omics mass spectrometry detection.

Related Services:

Full-Length Antibody Protein Sequence Analysis
De Novo Sequencing of Monoclonal Antibodies